US EditionPublished • loading... • Updated
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
ASC36 shows 91% greater weight loss efficacy than petrelintide in preclinical studies and aims for FDA IND submission in Q2 2026 as a once-monthly obesity treatment.
- Ascletis Pharma Inc. selected ASC36 as a clinical candidate and plans to submit an IND to the U.S. Food and Drug Administration in Q2 2026.
- Using its AISBDD and ULAP platforms, Ascletis designed ASC36 in-house to support once-monthly subcutaneous dosing with injection volume under one milliliter and scalable manufacturing.
- Study results indicate ASC36's half-life in NHP studies was approximately 15 days, three-fold longer than petrelintide, and caused-10.01% weight loss versus-5.25% in DIO rats.
- Ascletis Pharma Inc. will host a conference call in Mandarin at 10:00 a.m. China Standard Time on October 30, 2025 and plans to combine ASC36 with ASC35.
- Company rationale: Ascletis aims to make ASC36 a cornerstone therapy and basis for ASC36-based combination therapies for cardio-metabolic diseases, reflecting Jinzi Jason Wu, Ph.D.'s commitment to novel obesity treatments.
Insights by Ground AI
64 Articles
64 Articles
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans.
Ascletis bets on once-monthly ASC36 to fight obesity
HONG KONG, Oct. 30, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application (IND) for ASC36 for the treatment of obesity to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. AS…
Coverage Details
Total News Sources64
Leaning Left5Leaning Right6Center20Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 16%
C 65%
R 19%
Factuality
To view factuality data please Upgrade to Premium
